Allergy Therapeutics lands new £10mln financing facility
The new facility will run for up to five years and provides greater security.
Company
Allergy Therapeutics PLC
LON:AGY
Allergy Therapeutics PLC is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The company sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
298 stories · page 4 of 15
Allergy Therapeutics shares up 9% after it gets the FDA green light to begin phase I peanut allergy trial
Top-line data from the study are expected in the first half of next year, earlier than the originally intended readout
Allergy Therapeutics update contains positive aspects on the trials front
House broker finnCap left its target price of 65p unchanged following the half-year results.
Allergy Therapeutics primed for clinical progress; 2022 to be 'pivotal year'
The company is kicking on with work on key treatments for grass pollen and peanut allergies
Allergy Therapeutics hails positive results from field trial of its short-course grass pollen immunotherapy
The treatment led to a “clinically relevant improvement” symptoms, investors were told
Allergy Therapeutics looks forward to multiple inflection points in coming year
Next major milestones include results from the grass field trial in the autumn and a meeting with the US drug regulator for VLP Peanut ahead of the expected start of its peanut allergy study next year
Allergy Therapeutics says new allergy treatment wins German 'Most Innovative Product 2021' award
ImmunoBON was voted Most Innovative Product 2021 at the Pharma Trends Image and Innovation Awards
Allergy Therapeutics hails encouraging secondary endpoint results from peanut allergy vaccine study
"These results provide strong confidence in the beneficial immunologic mode of action of VLP Peanut”
FTSE 100 closes lower amid disappointing US jobs number and ahead of US Labor Day long weekend
The UK's premier share index finished down on Friday around 25 points, or 0.36%, at 7,138
Archive
US non-farm payroll additions being revised down after ADP payrolls shocker
The first Friday of the month means the US jobs report covering the preceding month. Wednesday's ADP payrolls report came in well short of expectations but it is rarely a reliable guide to the official figures
Allergy Therapeutics' peanut vaccine study further de-risks programme says broker
"There is substantial potential upside as VLP Peanut progresses through the clinic"
Allergy Therapeutics announces successful primary outcome of VLP Peanut 001 study
The findings support the VLP Peanut first-in-human Phase I study design, which is on track to start in the first quarter of next year
Allergy Therapeutics sees revenue and operating profit ahead of expectations
In the latest update, it told investors revenues, with an 8% rise to £84.3mln for the 12 months to June 30, would beat forecasts
Allergy Therapeutics showcases latest advances
Chief executive Manuel Llobet said: “Our research programmes are going beyond symptom management, to focus on directly treating the cause of allergy"
Allergy Therapeutics ends financial year on a high with operating profits 'well ahead' of expectations
Looking ahead, net sales for 2022 are expected to grow at low single-digit levels
Allergy Therapeutics sets up for big year as convenience factor proves a winner
Its Pollinex Quatro platform comprises four to six jabs, against up to 15 for rival injections
Allergy Therapeutics hails conclusion of 'breakthrough' hay fever field study
Results are due in the second half and will be used to design the company's phase III trial of Grass MATA MPL
Allergy Therapeutics makes strong start to financial year unimpeded by lockdown and Brexit
Allergy cited top-line momentum and operational efficiency for the strong growth in profitability
Allergy Therapeutics sees record cash balance as interim sales rise 7%
Allergy says it is fully funded for two crucial upcoming clinical trials from its own resources
Allergy Therapeutics says peanut allergy biomarker study gets underway
The work is being carried out by researchers from Imperial College London